Jun/28/2008 06:48
"If you start
putting a greater emphasis on doing [testing]
premarket, you greatly increase the cost of clinical
trials, which may lead companies to rethink
developing new drugs in this area," said Alan
Goldhammer, deputy vice president at Pharmaceutical
Research and Manufacturers of America. Of all the
dumb things to say this has to rank up at the top. Mr
Goldhammer is talking about the the Food and Drug
Administration considering tougher standards for new
and current diabetes drugs. Read
More...